Sernova Biotherapeutics Inc. (OTCMKTS:SEOVF) Sees Significant Decline in Short Interest

Sernova Biotherapeutics Inc. (OTCMKTS:SEOVF) saw a large drop in short interest in June. As of June 15th, there was short interest totaling 130,922 shares, a drop of 35.0% from the May 31st total of 201,477 shares. Based on an average daily trading volume, of 48,613 shares, the days-to-cover ratio is currently 2.7 days. Approximately 0.0% of the company’s shares are sold short.

Sernova Biotherapeutics Price Performance

Sernova Biotherapeutics stock opened at $0.09 on Friday. The stock has a market cap of $35.50 million, a price-to-earnings ratio of -2.35 and a beta of 0.82. Sernova Biotherapeutics has a 1 year low of $0.07 and a 1 year high of $0.16. The firm has a 50-day moving average of $0.11 and a two-hundred day moving average of $0.11.

Sernova Biotherapeutics (OTCMKTS:SEOVF) last issued its earnings results on Thursday, June 11th. The company reported ($0.01) EPS for the quarter, hitting analysts’ consensus estimates of ($0.01).

Sernova Biotherapeutics Company Profile

Sernova Biotherapeutics is a clinical‐stage biotechnology company focused on developing and commercializing cell‐based therapeutic technologies for patients with chronic and life‐threatening diseases. Headquartered in London, Ontario, Canada, the firm is advancing an implantable device platform designed to support the long-term survival and function of therapeutic cells. The company’s lead product candidate, known as the Cell Pouch System, is engineered to create a vascularized environment in which transplanted cells can thrive, with an initial emphasis on treating patients with type 1 diabetes.

In its core program, Sernova has initiated a Phase I/II clinical trial evaluating the safety and efficacy of the Cell Pouch System in individuals with type 1 diabetes who require islet cell transplantation.